TrialA Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Trial details
- Registry ID
- NCT04633122
- Phase
- Phase 2
Drug research
Sunitinib
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibNCT04633122 | Zai Lab (Shanghai) Co., Ltd. | Phase 2 | Completed | 2022-07-20Actual |
| (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal TumorsNCT05208047 | COGT | Phase 3 | Recruiting | 2025-09-30Actual |
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Trial details
- Registry ID
- NCT05208047
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |